Investigational drug · Phase 3
HPP737
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Psoriasis.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
5
Any phase or sponsor naming "HPP737"
First trial start
2025
Apr 18, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HPP737", any sponsor or status.
Conditions studied
As listed on its trial records.
- Psoriasis
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "HPP737" as an intervention, largest first.
- HPP737 in Adult Patients With Plaque PsoriasisPivotal-lookingCompleted
Newsoara Biopharma Co., Ltd.Industry
NCT07712731 · 607 participants · Start Apr 18, 2025 · Primary completion Apr 1, 2026
Drug: HPP737; Placebo matching HPP737 and 2 more · For: Psoriasis
Sites: Baotou, China; Beijing, China; Cangzhou, China · 60 sites in all
- HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.Pivotal-lookingCompleted
Newsoara Biopharma Co., Ltd.Industry
NCT07712705 · 515 participants · Start Apr 20, 2023 · Primary completion Sep 29, 2023
Drug: HPP737; Placebo matching HPP737 · For: Psoriasis
Sites: Beijing, China; Bengbu, China; Cangzhou, China · 50 sites in all
- Safety and Efficacy of HPP737 in Adult Patients With Plaque PsoriasisPivotal-lookingCompleted
Newsoara Biopharma Co., Ltd.Industry
NCT07707141 · 123 participants · Start Mar 3, 2021 · Primary completion Dec 20, 2021
Drug: HPP737 6mg and placebo; HPP737 10mg and placebo and 2 more · For: Psoriasis
Sites: Beijing, China; Hangzhou, China; Jinan, China · 8 sites in all
- Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy VolunteersStatus unknown
Newsoara Biopharma Co., Ltd.Industry
NCT04714294 · 84 participants (planned) · Start Sep 8, 2020 · Primary completion May 31, 2021
Drug: HPP737 or placebo · For: Healthy
Sites: Hangzhou, China
- HPP737 Substance Balance Study in HumanStatus unknown
Newsoara Biopharma Co., Ltd.Industry
NCT06584058 · 8 participants (planned) · Start Aug 30, 2024 · Primary completion Jul 30, 2025
Drug: HPP737 · For: Psoriasis
Sites: Suzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacokinetics, Safety and Tolerability of HPP737, a Novel PDE4 Inhibitor, in Healthy Chinese Participants: Phase I Study.
Ye L, Wang L, Tao X, et al. · Drug Des Devel Ther 2026
Also in development for Psoriasis
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- AK111Phase 32 trials
Akeso · Psoriasis, Skin Diseases, Ankylosing Spondylitis
- IBI112Phase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriasis
- Blinded EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
- CMAB015Phase 31 trial
Taizhou Mabtech Pharmaceutical Co.,Ltd · Psoriasis
- LZM012Phase 31 trial
Livzon Pharmaceutical Group Inc. · Psoriasis
- Open-Label EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.